<i>In vitro</i> activity of cefepime/taniborbactam and comparator agents against Gram-negative bacterial bloodstream pathogens recovered from patients with cancer.

JAC Antimicrob Resist · 2024 · PMC11005172 · PMID 38601790

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantP < 0.0001actually significant

maltophilia ), whereas cefepime/taniborbactam showed activity against 97.6% of the same isolates, and these differences were highly significant ( P < 0.0001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.